Earth Science Tech, Inc. reports news on its role as a diversified healthcare and wellness holding company with OTC-traded common stock. Recurring updates cover its compounding pharmacy operations, including RxCompoundStore.com and Mister Meds, and telemedicine platforms such as Peaks Curative, DOConsultation, MOCTeledoc and MyOnlineConsultation.com.
Company announcements also address financial results, public-company governance, auditor and investor-relations changes, industry-classification updates, FINRA quotation clearance, and portfolio activity outside healthcare through Avenvi real estate and asset management and MagneChef direct-to-consumer products.
Earth Science Tech (OTC: ETST) engaged Semple, Marchal & Cooper, LLP as its new independent PCAOB auditor on Feb. 17, 2026 to upgrade audit capabilities and governance.
The company cited rising consolidated accounting complexity across pharmacy compounding, telemedicine and real estate and said the regional firm’s broader resources and specialized expertise will optimize auditing efficiencies and better match ETST’s current operational scale.
Earth Science Tech (OTC: ETST) reported Q3 fiscal 2026 results for the quarter ended December 31, 2025, with revenue of $8.4M (+14.1% YoY) and net income of $910K (+341% YoY). Gross profit rose $1.3M to $6.4M (76.3% margin). Adjusted EBITDA was $1.2M. Cash on hand fell to $416K as inventory and operations increased. The company reported Peaks telemedicine revenue surpassing $2.0M in under a year and repurchased shares during the period.
Earth Science Tech (OTC: ETST) will release financial results for the three months ended December 31, 2025 after the close of trading on Tuesday, February 17, 2026. Investors may submit questions in advance and listen via conference call or live webcast.
Conference call is scheduled for 5:00 p.m. Eastern on February 17, 2026, with toll‑free and international dial‑in numbers, passcode, and replay webcast links provided for investor access.
Earth Science Tech (OTC: ETST) issued a directive on Jan 6, 2026 asking financial data providers, news aggregators, and brokerages to update its SEC-registered industry classification to SIC 2834 (Pharmaceutical Preparations).
The company says it completed a strategic pivot to pharmaceutical operations in 2022, operates pharmaceutical compounding and telemedicine businesses (RxCompoundStore.com, Mister Meds, Peaks Curative, DOConsultations), and reports that clearance of its 15c-211 was the final regulatory step to establish ETST as a pharmaceutical entity. ETST provided its SEC CIK 0001538495 and is engaging major data desks to remove legacy CBD/cannabis tags.
Earth Science Tech (OTC: ETST) engaged Hayden IR on Jan 5, 2026 to expand investor outreach, messaging, and market awareness after completing FINRA 15c-211 clearance. Hayden IR will support institutional and retail outreach, corporate access, and public disclosure support as ETST scales operations across pharmacy, telemedicine, and direct-to-consumer channels.
Management highlighted first-half fiscal 2026 results of $17.8M revenue, $1.4M net income, $1.18M operating cash flow, and gross margins >70%; Hayden IR cited operating leverage and CEO alignment (over 122M shares held).
Earth Science Tech (OTC: ETST) announced that the Financial Industry Regulatory Authority processed a Form 211 filed by a sponsoring broker-dealer on Dec 12, 2025, clearing the broker-dealer to initiate priced quotations for ETST within four days of Dec 12, 2025. The company described this clearance as a strategic milestone expected to help build long-term shareholder value, improve liquidity, and increase visibility for its business plan. The release notes that FINRA's processing of Form 211 does not constitute FINRA approval of the security, the issuer, or the issuer's business and relates solely to the broker-dealer's compliance with applicable FINRA and SEC rules.
Earth Science Tech (OTC: ETST) reported strong Second Fiscal Quarter results for the period ended September 30, 2025. Key financials: Total Assets $8.66M (+71.64% YoY, +22.65% YTD from $7.07M), Quarterly Revenue $9.05M (+6.24%), Gross Profit $6.72M (+7.3%), and Quarterly Net Profit $0.94M (+18.48%). Outstanding common shares fell to 292.8M, a 3.57% reduction YoY. Management described the quarter as execution of its strategy to acquire and scale high-potential operating businesses and cited asset growth and share reduction as evidence of shareholder-value focus.
Earth Science Tech (OTC: ETST) has significantly enhanced its share repurchase program, increasing the total authorization to $10 million and extending it through December 31, 2027. Since the program's inception in January 2024, ETST has already invested $1.83 million to repurchase 20.83 million shares.
The company currently has a remaining authorization of $8.17 million for future share repurchases. The program allows for discretionary repurchases through open market or private transactions, subject to market conditions and other factors, and can be suspended or discontinued at any time.
Earth Science Tech (OTC:ETST) announced its Board of Directors has approved a reduction in authorized common stock from 350 million to 300 million shares. The company currently has approximately 294.3 million shares outstanding.
CEO Giorgio R. Saumat emphasized that this strategic decision reflects the Board's confidence in the company's trajectory and demonstrates their commitment to preventing unnecessary shareholder dilution while protecting long-term shareholder value.
Earth Science Tech (OTC: ETST) reported significant growth in its first fiscal quarter ended June 30, 2025. The company's total assets increased 61% to $7.69 million, while revenue reached $8.7 million, up from $8.5 million year-over-year.
During the quarter, ETST executed several strategic acquisitions, including 100% acquisition of Las Villas Health Care and DOConsultation, along with 80% ownership of Magnefuse and Alicat (MagneChef Portfolio). The company reduced its outstanding shares by 4.78% to 294.3 million shares and maintained a cash position of $0.88 million after funding acquisitions.
Post-quarter developments include joining the OTCID Tier, expanding MisterMeds operations in Texas, and initiating Avenvi's first residential development project.